Division of Spinal Surgery/Departments of Orthopaedic and Neurosurgery, NYU Medical Center, NY Spine Institute, New York, NY, USA.
Department of Orthopedic Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA.
J Clin Neurosci. 2020 Oct;80:223-228. doi: 10.1016/j.jocn.2020.07.047. Epub 2020 Aug 27.
The aim of this study was to investigate the cost utility of treating non-frail versus frail or severely frail adult spinal deformity (ASD) patients. 79 surgical ASD patients >18 years with available frailty and ODI data at baseline and 2-years post-surgery (2Y) were included. Utility data was calculated using the ODI converted to the SF-6D. QALYs utilized a 3% discount rate to account for decline to life expectancy (LE). Costs were calculated using the PearlDiver database. ICER was compared between non-operative (non-op.) and operative (op.) NF and F/SF patients at 2Y and LE. When compared to non-operative ASD, the ICER was $447,943.96 vs. $313,211.01 for NF and F/SF at 2Y, and $68,311.35 vs. $47,764.61 for NF and F/SF at LE. Frail and severely frail patients had lower cost per QALY compared to not frail patients at 2Y and life expectancy, and had lower ICER values when compared to a non-operative cohort of ASD patients. While these results support operative correction of frail and severely frail patients, it is important to note that these patients are often at worse baseline disability, which is closely related to frailty scores, and have more opportunity to improve postoperatively. Furthermore, there may be a threshold of frailty that is not operable due to the risk of severe complications that is not captured by this analysis. While future research should investigate economic outcomes at extended follow up times, these findings support the cost effectiveness of ASD surgery at all frailty states.
本研究旨在探讨治疗非脆弱型与脆弱型或严重脆弱型成人脊柱畸形(ASD)患者的成本效用。共纳入 79 名年龄>18 岁的成年 ASD 患者,他们在基线和术后 2 年(2Y)时具有虚弱和 ODI 数据,并且可获得 SF-6D 转换的 ODI 数据来计算效用数据。QALYs 采用 3%的贴现率来考虑对预期寿命(LE)的衰减。使用 PearlDiver 数据库计算成本。在 2Y 和 LE 时,比较非手术(非 op.)和手术(op.)NF 和 F/SF 患者之间的 ICER。与非手术 ASD 相比,NF 和 F/SF 在 2Y 时的 ICER 为$447,943.96 vs. $313,211.01,在 LE 时的 ICER 为$68,311.35 vs. $47,764.61。与非脆弱型患者相比,脆弱型和严重脆弱型患者在 2Y 和预期寿命时每 QALY 的成本更低,并且与非手术 ASD 患者队列相比,ICER 值更低。虽然这些结果支持对脆弱型和严重脆弱型患者进行手术矫正,但重要的是要注意,这些患者的基线残疾程度往往更差,这与虚弱评分密切相关,并且术后有更多的改善机会。此外,由于本分析未捕获到严重并发症的风险,可能存在一个不可操作的虚弱阈值。虽然未来的研究应该调查延长随访时间的经济结果,但这些发现支持在所有虚弱状态下 ASD 手术的成本效益。